Quantum Immunologics: Going to School

Quantum Immunologics Inc. is developing an autologous dendritic cell therapy that it says applies lessons learned from Dendreon Corp.'s path through the clinic with Provenge sipuleucel-T.

Where Quantum says it is differentiated from other cancer immunotherapy companies is the antigen it uses to target the cancer cells, a cell surface receptor known as oncofetal antigen/immature laminin receptor protein (OFA/iLRP).

"If you look at historical data and references, over 85% of patients

Read the full 693 word article

How to gain access

Continue reading with a
two-week free trial.